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Viral metagenomics on pericardial fluids 
L. Fancello* (Marseille, FR) 
Objectives: Viruses are the most abundant and diverse biological entities and important human 
pathogens. However, to date little is known about viral diversity, especially in human body, as their 
rapid evolution and scarce cultivability makes it difficult their study. Moreover classic diagnostic 
methods often fail to identify divergent viruses in clinical specimens because of their high specificity. 
At present several common pathologies with unknown aetiology are presumed to be of viral origin and 
among them pericarditis, for which in 40-85% of cases no identifiable cause has been found. In this 
work we used a metagenomic approach to investigate the viral community colonizing human 
pericardial fluid and to identify new divergent viruses, not detected by routine screenings, likely to be 
responsible for unexplained cases of pericarditis.  
Methods: We studied 8 pericardial fluid samples: 6 from patients affected by pericarditis of unknown 
aetiology; one from a patient affected by pericarditis caused by herpesvirus 3 (positive control); one 
consisting in the pool of pericardial fluids from 5 different individuals affected by a pericarditis of non-
infectious origin (negative control). Viral nucleic acids extracted from samples were amplified in a 
sequence-independent way and mass sequenced. 
Results: Interestingly, analysis of obtained sequences showed in one patient the presence of 
considerable amounts of torque teno virus, which, to our knowledge, had not been found in pericardial 
fluid yet. This virus and its potential association to human pathologies still are poorly understood  and 
constitute an active domain of research. Moreover 3 further patients presented in their pericardial fluid 
some sequences of Staphylococcus phages, Streptococcus phages and Pseudomonas phages which 
we hypothesize to be time-persistent traces of ancient infection by their corresponding microbial hosts. 
It is likely that late diagnostic analyses failed to recover these bacterial pathogens as their abundance 
had already fallen under the detection limit whereas their predator populations (phages) are detectable 
later in time, according to the Lotka-Volterra model. 
Conclusion: The unbiased and "a priori"-free approach of metagenomics allowed original observations 
on pericardial fluid virome, as the presence of torque teno virus and of unknown sequences. Still 
further studies have to be done to clarify the involvement of unknown viruses in pericarditis aetiology. 
LB2769
A randomised, placebo controlled Phase 1 first-in-human study of a novel 3-antigen 
Staphylococcus aureus vaccine in healthy adults 
P. Richmond*, M. Nissen, H. Marshall, S. Shakib, P. Hodsman, Q. Jiang, D. Rill, J. Baber, J. Eiden, 
K.U. Jansen, A. Anderson, E. Zito, D. Girgenti (Perth, Brisbane, Adelaide, Melbourne, AU; 
Collegeville, US; Sydney, AU; Pearl River, US) 
Background: Staphylococcus aureus is a major cause of serious healthcare- and community-
associated infection and the increase in antibiotic-resistance highlights the unmet medical need for an 
effective prophylactic vaccine. A novel vaccine candidate comprised of capsular polysaccharide 
serotypes 5 and 8 (CP5 and CP8) conjugated to CRM197 and a recombinant surface-expressed 
protein antigen, clumping factor A (rClfAm) was evaluated.  
Objectives: This Phase I double-blind randomized placebo controlled study assessed the safety, 
tolerability and immunogenicity of 3 ascending dose levels of the candidate vaccine in healthy adults.  
Methods: 408 participants (96 subjects age 18-24 years, 312 subjects age 50-85 years) were 
randomized at 5 Australian centres to receive a single dose of placebo or one of 3 dose levels active 
vaccine:  Low (10 μg each CP5 & CP8 conjugates, 20 μg rClfAm), Mid (30 μg CP5 & CP8 conjugates, 
60 μg rClfAm) or High (100 μg CP5 & CP8 conjugates, 200 μg rClfAm). Local reactions and systemic 
events were recorded for 14 days. Immunogenicity was assessed using antigen-specific competitive 
Luminex immuno assays (cLIAs) and opsonophagocytic assays (OPAs),  
Results: The vaccine was well tolerated in both age groups. Local reactions were mostly mild and 
more common after active vaccine (26.5-50.5%) than placebo (11.8%) administration. Local reactions 
were reduced in the older cohort (17- 44%) compared to young adults (33-71%). Systemic events in 
both age groups were similar among placebo and all 3 vaccine dosages. cLIA GMCs and OPA GMTs 
showed substantial increases in antibody levels after vaccination for all 3 vaccine components at all 
dose levels.  No changes in antibody levels were seen in placebo recipients. Among actively 
vaccinated groups, in young adults, the cLIA geometric mean fold rise (GMFR) ranged from 67.7 to 
97.6 for CP5, 16.9 to 29.3 for CP8 and 18.0 to 33.5 for rClfAm. Among the older adult groups, the cLIA 
GMFR ranged from 29.2 to 83.7 for CP5, 14.1 to 31.0 for CP8 and 45.8 to 48.7 for rClfAm, with a dose 
response observed for CP5 and CP8 cLIA in older adults but not the young adults. OPA GMFRs to 
CP5 and CP8 strains ranged from 15.4 to 73.5 and from 13.9 to 34.7 respectively. 
Summary: The 3-component S. aureus candidate vaccine was well tolerated and immunogenic in 
adults across a wide age range inducing functional opsonophagocytic antibody. 
LB2770
Improved in vivo model for P. aeruginosa burn wound infections 
A.-L. Forslund, E. Nilsson, E. Näslund Salomonsson, J. Näslund , K. Kuoppa, Å. Forsberg, L. Noppa* 
(Umea, SE) 
Objectives: Pseudomonas aeruginosa (P. a) is one of the most prevalent bacterial pathogens in 
severe burn wound infections. Once a threshold concentration of bacteria is reached in the eschar 
there is often a rapid spread through the bloodstream, causing bacteraemia that can be followed by 
multi-organ failure and death. The high levels of intrinsic as well as acquired antibiotic resistance of P. 
a is a major concern and highlights the great need for new innovative research and strategies to 
develop novel antimicrobials. A critical step in evaluation of antimicrobials is the availability of relevant 
in vivo infection models. The aim of this study is to improve a murine model of lethal burn wound 
infection caused by P. a by using bioluminescent bacteria which allows sensitive real-time monitoring 
of the bacterial burden in living animals. 
Methods: BALB/c mice were pre-treated 3 times with 200 mg/kg cyclophosphamide given i.p. in order 
to induce immunosuppression. The treatment was carried out every second day and the final dose 
was administered either 3 days or 1 day prior to infection. Mice were anaesthetised, shaved and the 
burn wound was inflicted by using a heated metal rod before topical inoculation with strain 
PAO1::p16Slux (kindly provided by Prof. O’Gara, Biomerit Research Center, Ireland). The animals 
were treated daily with analgetica in order to relieve pain. Infection was followed during five days and 
bacterial numbers were monitored daily using the NightOWL® imaging system. As a positive control 
for topical infection treatment, one group of mice was treated twice daily with a quinolone antibiotic, 
Ciloxan®. 
Results: Bioluminescence images of the infection showed that P. a rapidly colonized the skin and 48h 
post-infection the bacteria had disseminated from the infection site and reached the bloodstream and 
organs which was also confirmed by viable count. No difference in bacterial load in organs was 
observed between the luminescent strain and the wild-type strain. Treatment with Ciloxan® effectively 
lowered the bacterial burden on the skin and after 24h all bacteria were eradicated. 
Conclusion: Bioluminescence in vivo imaging allows for a non-invasive and real-time monitoring of the 
infection processes in individual animal over time. The present novel bioluminescent P. a mouse 
model for lethal burn wound infection and sepsis will be useful in the evaluation of new antimicrobials 
and in efficacy studies of treatment regimens against P. a infections. 
LB2771
Renal failure, fever, and leukocytosis all predict treatment failure in Clostridium difficile 
infection (CDI), but renal failure is the only predictor of recurrent CDI 
M.P. Bauer*, M. Miller, D.N. Gerding, E.J. Kuijper, S.L. Gorbach (Leiden, NL; Montreal, CA; Chicago, 
Boston, US) 
Objectives:The distinction between non-severe and severe C. difficile infection (CDI), which carries a 
higher risk of treatment failure and recurrence, is difficult to make at the time of diagnosis. The 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) has issued a guidance 
document that suggests markers of severe CDI. We aimed to investigate the prognostic value of these 
markers in patients participating in a randomized controlled trial. 
Methods:We used the database of a randomized controlled trial comparing vancomycin to fidaxomicin 
for the treatment of CDI and consisting of 1105 patients. Three of the ESCMID markers, fever (body 
temperature > 38.5°C), leukocytosis (leukocyte count > 15 × 10^9/L) and renal failure (creatinine level 
>= 133 μmol/L) were available for evaluation. 
Results:Fever (risk ratio: 2.45; 95% CI: 1.07 – 5.61), leukocytosis (risk ratio: 2.29; 95% CI: 1.63 – 
3.21) and renal failure (risk ratio: 2.52; 95% CI: 1.82 –  3.50) were all associated with initial failure of 
CDI therapy. Patients with renal failure tended to have a delayed time to resolution of diarrhea, but the 
difference compared to those with normal renal function was not significant. Of the three markers, only 
renal failure was a significant predictor of recurrence after successful therapy (risk ratio: 1.45; 95% CI: 
1.05 – 2.02). Fidaxomicin was associated with a 60% reduction in recurrences relative to vancomycin 
in patients with renal failure at baseline (P = 0.007). 
Conclusion: Fever, leukocytosis and renal failure were predictors of initial failure of CDI therapy, but 
only renal failure predicted recurrence. Patients with renal failure treated with fidaxomicin suffered 
significantly fewer recurrences than those treated with vancomycin. 
LB2772
An improved canSNP-typing scheme for rapid and robust real-time PCR detection of Coxiella 
burnetii obtained by adding four new sequenced genomes 
A. Macellaro*, K. Svensson, A. Sjödin, D. Frangoulidis, M. Forsman (Umea, SE; Munich, DE) 
Objective: The highly clonal organism Coxiella burnetii that causes Q fever is difficult to isolate and 
cultivate, and BSL3 requirements are essential due to its infectiousness. Therefore few genomes are 
available to date. We here present four new genomes of C. burnetii with the objective to develop an 
improved canonical SNP (canSNP) typing scheme, based on these four new genomes and those 
seven already publically available genomes.  
Methods: The genomes of C2, Innsbruck, Ohio, and Scurry, were sequenced by Illumina technology, 
de novo assembled using Velvet, and aligned by MAUVE together with seven publically available 
genomes. In total 20 sets of canSNPs were identified, each defining one branch in the phylogenetic 
tree generated by the neighbor-joining method using MEGA5 on 10 901 SNPs out of in total 1 702 067 
positions. Only 44 out of 10 901 SNPs did not fit the tree structure, indicating a highly clonal 
population structure. The phylogenetic tree structure was in agreement with results from 17 markers 
multi-loci variable number tandem repeat analysis (MLVA) on the in total 11 available genomes. We 
selected nine SNPs defining major branches in the tree to be included in the real-time PCR detection 
methods used (Svensson et al (2009) and BactSNiP SNP Screening (Frangoulidis, unpublished)). 
Results: We could hereby classify 36 C. burnetii strains into five genotypes, showing the three 
previously published plasmid types QpH1 (two subgroups), QpDG, and QpRS; and the chromosome 
integrated plasmid type, respectively. The additional 11 canSNPs which define deeper branches in the 
tree and thus gives a higher typing resolution will be run next and MLVA data will be completed for the 
36 strains. 
Conclusions: Rapid detection of Coxiella burnetii is important for correct diagnosis of infected patients 
or animals. Real-time PCR assays, based on phylogenetically robust SNP markers allows the typing 
resolution to be chosen depending on the purpose of the typing, and may be helpful tools in 
epidemiological investigations to identify and trace infectious sources in animals and the environment. 
LB2773
An Unexpected Source of False-Positive Bordetella pertussis (BP) Polymerase Chain Reaction 
(PCR): the Vaccine 
H. Salimnia*, P.R. Lephart, B. Asmar, D. Prebelich, E. Paulson, M.R. Fairfax (Detroit, US) 
Objectives: Michigan (USA) is experiencing an increased number of cases of BP disease: between 
Jan. and Oct. 2010, 1092 cases were reported as opposed to 315 during all of 2008.  Our laboratory 
employs a multiplex, real-time PCR assay (EraGen Biosciences, Madison, WI, USA) to identify BP 
and B. parapertussis (BPP) by targeting IS481 and IS 1001 respectively. Over 2 days in December 
2010, we received 13 nasal wash specimens from one pediatrician’s office. All 13 tested positive for 
BP, although most of the children did not have symptoms of BP. Suspecting contamination, we began 
an investigation to determine the cause of this pseudo-outbreak.   
Methods: Nasal washes (0.2 ml) are extracted with the EasyMag® (bioMerieux, Durham, NC) as 
described by the manufacturer, and 5 microliters of each extract is subjected to PCR. BP and BPP 
PCR products can be distinguished based on their different melting temperatures. We collected 
samples of wash solution, syringes used in collecting the nasal wash, and an empty vial of the DTap-
IPV (Diphtheria/ Tetanus Toxoids/Acellular Pertussis Antigens/Inactivated Poliovirus) component of 
the Pentacel® (Sanofi Pasteur, Swiftwater, PA, USA) vaccine. Sterile water was injected into the vial, 
extracted and tested by PCR like a nasal wash specimen. Subsequently vaccine  from previously 
unopened vials of Infanrix® (Tdap; GlaxoSmithKline, Research Triangle Park, NC), Adacel® (TDaP; 
Sanofi Pasteur), and Pentacel® (DTaP-IPV component only) were extracted, and tested in the same 
way. The vaccine preparation area was wiped with moistened swabs which were also tested.  
Results: All 13 patient specimens were positive with high crossing thresholds (CT: 38-39; roughly = 
102 copies/ml).  The rinse from the empty Pentacel vial was positive (CT: 19.6; roughly 108  genome 
copies/ml). Supplies for collection of nasal washes were negative. Adacel and Pentacel from fresh 
bottles were strongly positive at a dilution of 1/100, while Infanrix was negative. The wipe tests were 
positive confirming that the vaccine preparation area was contaminated with BP genomes.   
Conclusions: 1. Pentacel and Adacel contain large amounts of BP DNA which can cause false-positive 
PCR results for BP. 2. Precautions should be taken to avoid aerosol creation at the time of 
vaccination. 3. Preparation and injection of vaccine should take place in a different room from 
diagnostic specimen collection. 
